Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Review Article

The Function of LncRNA FTX in Several Common Cancers

Author(s): Yexiang Lin, Yujie Shen, Jinlan Chen, Chengyu Hu, Zixian Zhou and Chengfu Yuan*

Volume 27, Issue 20, 2021

Published on: 29 October, 2020

Page: [2381 - 2386] Pages: 6

DOI: 10.2174/1381612826666201029164036

Price: $65

Abstract

Background: LncRNA is a kind of non-coding RNA and its research is more popular in recent years, which has more than 200 nucleotides. It plays a significant part in various biological functions, including chromosome modification, genome modification, transcriptional activation, transcriptional interference, and other processes. FTX, at the center of the X chromosome inactivation and it has been shown that lncRNA FTX regulates cancer cells’ development, migration, and invasion in many studies.

Methods: Relevant literature was collected through the PubMed system search and is summarized in this article.

Results: LncRNA FTX abnormally increased in tumor cells, such as liver cancer, stomach cancer, leukemia, renal cell carcinoma, colorectal cancer, glioma, osteosarcoma, etc. However, the expression level decreased in temporal lobe epilepsy, liver cirrhosis, heart failure, etc.

Conclusion: FTX may be an important regulatory factor and a potential therapeutic target in cancers.

Keywords: LncRNA FTX, cancer, temporal lobe epilepsy, cirrhosis, heart failure, osteosarcoma.

« Previous Next »
[1]
Chureau C, Chantalat S, Romito A, et al. Ftx is a non-coding RNA which affects Xist expression and chromatin structure within the X-inactivation center region. Hum Mol Genet 2011; 20(4): 705-18.
[http://dx.doi.org/10.1093/hmg/ddq516] [PMID: 21118898]
[2]
Li X, Zhao Q, Qi J, et al. lncRNA Ftx promotes aerobic glycolysis and tumor progression through the PPARγ pathway in hepatocellular carcinoma. Int J Oncol 2018; 53(2): 551-66.
[http://dx.doi.org/10.3892/ijo.2018.4418] [PMID: 29845188]
[3]
Huang S, Zhu X, Ke Y, et al. LncRNA FTX inhibition restrains osteosarcoma proliferation and migration via modulating miR-320a/TXNRD1. Cancer Biol Ther 2020; 21(4): 379-87.
[http://dx.doi.org/10.1080/15384047.2019.1702405] [PMID: 31920141]
[4]
Li B, Ren P, Wang Z. Long non-coding RNA Ftx promotes osteosarcoma progression via the epithelial to mesenchymal transition mechanism and is associated with poor prognosis in patients with osteosarcoma. Int J Clin Exp Pathol 2018; 11(9): 4503-11.
[PMID: 31949847]
[5]
Ho TH, M.D. PK, Parker AS, et al. Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma. Urol Oncol 2015; 33(1): 23.
[http://dx.doi.org/10.1016/j.urolonc.2014.10.014]
[6]
He X, Sun F, Guo F, et al. Knockdown of Long Noncoding RNA FTX Inhibits Proliferation, Migration, and Invasion in Renal Cell Carcinoma Cells. Oncol Res 2017; 25(2): 157-66.
[http://dx.doi.org/10.3727/096504016X14719078133203] [PMID: 27983937]
[7]
Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin 2014; 64(2): 104-17.
[http://dx.doi.org/10.3322/caac.21220] [PMID: 24639052]
[8]
Yang Y, Zhang J, Chen X, et al. LncRNA FTX sponges miR-215 and inhibits phosphorylation of vimentin for promoting colorectal cancer progression. Gene Ther 2018; 25(5): 321-30.
[http://dx.doi.org/10.1038/s41434-018-0026-7] [PMID: 29925853]
[9]
Guo XB, Hua Z, Li C, et al. Biological significance of long non-coding RNA FTX expression in human colorectal cancer. Int J Clin Exp Med 2015; 8(9): 15591-600.
[PMID: 26629053]
[10]
Chen DL, Lu YX, Zhang JX, et al. Long non-coding RNA UICLM promotes colorectal cancer liver metastasis by acting as a ceRNA for microRNA-215 to regulate ZEB2 expression. Theranostics 2017; 7(19): 4836-49.
[http://dx.doi.org/10.7150/thno.20942] [PMID: 29187907]
[11]
Lin Y, Jin Y, Xu T, Zhou S, Cui M. MicroRNA-215 targets NOB1 and inhibits growth and invasion of epithelial ovarian cancer. Am J Transl Res 2017; 9(2): 466-77.
[PMID: 28337275]
[12]
Vychytilova-Faltejskova P, Merhautova J, Machackova T, et al. MiR-215-5p is a tumor suppressor in colorectal cancer targeting EGFR ligand epiregulin and its transcriptional inducer HOXB9. Oncogenesis 2017; 6(11): 399.
[http://dx.doi.org/10.1038/s41389-017-0006-6] [PMID: 29199273]
[13]
Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol 2006; 2(9): 494-503.
[http://dx.doi.org/10.1038/ncpneuro0289]
[14]
Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114(2): 97-109.
[http://dx.doi.org/10.1007/s00401-007-0243-4] [PMID: 17618441]
[15]
Zhang W, Bi Y, Li J, et al. Long noncoding RNA FTX is upregulated in gliomas and promotes proliferation and invasion of glioma cells by negatively regulating miR-342-3p. Lab Invest 2017; 97(4): 447-57.
[http://dx.doi.org/10.1038/labinvest.2016.152] [PMID: 28112756]
[16]
Zhu L, Jia R, Zhang J, Li X, Qin C, Zhao Q. Quantitative Proteomics Analysis Revealed the Potential Role of lncRNA Ftx in Promoting Gastric Cancer Progression. Proteomics Clin Appl 2020; 14(1): e1900053.
[http://dx.doi.org/10.1002/prca.201900053] [PMID: 31709769]
[17]
Döhner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med 2015; 373(12): 1136-52.
[http://dx.doi.org/10.1056/NEJMra1406184] [PMID: 26376137]
[18]
Liu B, Ma X, Liu Q, Xiao Y, Pan S, Jia L. Aberrant mannosylation profile and FTX/miR-342/ALG3-axis contribute to development of drug resistance in acute myeloid leukemia. Cell Death Dis 2018; 9(6): 688.
[http://dx.doi.org/10.1038/s41419-018-0706-7] [PMID: 29880818]
[19]
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61(2): 69-90.
[http://dx.doi.org/10.3322/caac.20107] [PMID: 21296855]
[20]
Liu F, Yuan JH, Huang JF, et al. Long noncoding RNA FTX inhibits hepatocellular carcinoma proliferation and metastasis by binding MCM2 and miR-374a. Oncogene 2016; 35(41): 5422-34.
[http://dx.doi.org/10.1038/onc.2016.80] [PMID: 27065331]
[21]
Liu Z, Dou C, Yao B, et al. Ftx non coding RNA-derived miR-545 promotes cell proliferation by targeting RIG-I in hepatocellular carcinoma. Oncotarget 2016; 7(18): 25350-65.
[http://dx.doi.org/10.18632/oncotarget.8129] [PMID: 26992218]
[22]
Zhao Q, Li T, Qi J, Liu J, Qin C. The miR-545/374a cluster encoded in the Ftx lncRNA is overexpressed in HBV-related hepatocellular carcinoma and promotes tumorigenesis and tumor progression. PLoS One 2014; 9(10): e109782.
[http://dx.doi.org/10.1371/journal.pone.0109782] [PMID: 25299640]
[23]
Li X, Giri V, Cui Y, Yin M, Xian Z, Li J. LncRNA FTX inhibits hippocampal neuron apoptosis by regulating miR-21-5p/SOX7 axis in a rat model of temporal lobe epilepsy. Biochem Biophys Res Commun 2019; 512(1): 79-86.
[http://dx.doi.org/10.1016/j.bbrc.2019.03.019] [PMID: 30871773]
[24]
Liu X, Li C, Zhu J, Li W, Zhu Q. Dysregulation of FTX/miR-545 signaling pathway downregulates Tim-3 and is responsible for the abnormal activation of macrophage in cirrhosis. J Cell Biochem 2018.
[PMID: 30304545]
[25]
Yang X, Tao L, Zhu J, Zhang S. Long Noncoding RNA FTX Reduces Hypertrophy of Neonatal Mouse Cardiac Myocytes and Regulates the PTEN/PI3K/Akt Signaling Pathway by Sponging MicroRNA-22. Med Sci Monit 2019; 25: 9609-17.
[http://dx.doi.org/10.12659/MSM.919654] [PMID: 31840653]
[26]
Qian W, Yu D, Zhang J, et al. Wogonin Attenuates Isoprenaline-Induced Myocardial Hypertrophy in Mice by Suppressing the PI3K/Akt Pathway. Front Pharmacol 2018; 9: 896.
[http://dx.doi.org/10.3389/fphar.2018.00896] [PMID: 30150938]
[27]
Yang X, Li X, Lin Q, Xu Q. Up-regulation of microRNA-203 inhibits myocardial fibrosis and oxidative stress in mice with diabetic cardiomyopathy through the inhibition of PI3K/Akt signaling pathway via PIK3CA. Gene 2019; 715: 143995.
[http://dx.doi.org/10.1016/j.gene.2019.143995] [PMID: 31336140]
[28]
Crackower MA, Oudit GY, Kozieradzki I, et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 2002; 110(6): 737-49.
[http://dx.doi.org/10.1016/S0092-8674(02)00969-8] [PMID: 12297047]
[29]
Moe GW, Marín-García J. Role of cell death in the progression of heart failure. Heart Fail Rev 2016; 21(2): 157-67.
[http://dx.doi.org/10.1007/s10741-016-9532-0] [PMID: 26872675]
[30]
Ashkenazi A, Fairbrother WJ, Leverson JD, Souers AJ. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nat Rev Drug Discov 2017; 16(4): 273-84.
[http://dx.doi.org/10.1038/nrd.2016.253] [PMID: 28209992]
[31]
Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2014; 15(1): 49-63.
[http://dx.doi.org/10.1038/nrm3722] [PMID: 24355989]
[32]
Long B, Li N, Xu XX, et al. Long noncoding RNA FTX regulates cardiomyocyte apoptosis by targeting miR-29b-1-5p and Bcl2l2. Biochem Biophys Res Commun 2018; 495(1): 312-8.
[http://dx.doi.org/10.1016/j.bbrc.2017.11.030] [PMID: 29117536]

Rights & Permissions Print Cite
Article Metrics
35
1
© 2024 Bentham Science Publishers | Privacy Policy